MeSH term
Frequency | Condition_Probility | Adult | 53 | 0.0 |
Comparative Study | 23 | 0.0 |
Humans | 133 | 0.0 |
Biopsy | 3 | 0.0 |
English Abstract | 8 | 0.0 |
Protein-Tyrosine Kinase/*genetics/metabolism | 2 | 4.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Biological Markers/blood | 2 | 0.0 |
Case-Control Studies | 10 | 0.0 |
Female | 102 | 0.0 |
Fetal Blood/*chemistry | 3 | 5.0 |
Maternal-Fetal Exchange | 4 | 3.0 |
Pregnancy | 76 | 1.0 |
Prenatal Diagnosis/*methods | 2 | 1.0 |
Research Support, Non-U.S. Gov't | 63 | 0.0 |
Birth Weight/physiology | 2 | 40.0 |
Embryonic and Fetal Development/physiology | 3 | 3.0 |
Fetal Growth Retardation/*blood | 2 | 13.0 |
Infant, Newborn | 43 | 0.0 |
Insulin-Like Growth Factor Binding Protein 3/*blood | 2 | 7.0 |
Blood Flow Velocity | 3 | 3.0 |
Fetal Growth Retardation/*physiopathology | 3 | 30.0 |
Pregnancy Trimester, Second | 6 | 2.0 |
Prospective Studies | 10 | 0.0 |
Ultrasonography, Prenatal | 7 | 10.0 |
Fetal Growth Retardation/*etiology | 6 | 54.0 |
Research Support, U.S. Gov't, P.H.S. | 27 | 0.0 |
Stilbenes/pharmacology | 2 | 6.0 |
Blotting, Western | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Pregnancy/*metabolism | 2 | 3.0 |
Pregnancy Trimester, Third | 9 | 4.0 |
Reference Values | 8 | 0.0 |
Aged | 5 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Male | 20 | 0.0 |
Middle Aged | 7 | 0.0 |
Sensitivity and Specificity | 9 | 0.0 |
Transfection | 2 | 0.0 |
src Homology Domains | 2 | 0.0 |
Birth Weight | 14 | 8.0 |
Fetal Growth Retardation/*diagnosis | 4 | 50.0 |
Gestational Age | 23 | 2.0 |
Infant, Small for Gestational Age | 5 | 25.0 |
Pregnancy Trimester, First/*blood | 2 | 33.0 |
Fetal Growth Retardation/*metabolism | 4 | 20.0 |
Placenta/*chemistry | 3 | 8.0 |
Microscopy, Electron | 2 | 0.0 |
Animals | 13 | 0.0 |
Placenta/*metabolism | 3 | 1.0 |
Sheep | 2 | 0.0 |
Uterus/blood supply | 2 | 28.0 |
Cell Line | 4 | 0.0 |
*Gene Amplification | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
Fetal Growth Retardation/physiopathology | 3 | 60.0 |
Pregnancy Trimester, First | 4 | 1.0 |
Adolescent | 5 | 0.0 |
Mutation | 2 | 0.0 |
Predictive Value of Tests | 13 | 0.0 |
ROC Curve | 2 | 1.0 |
Time Factors | 3 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
Vascular Endothelial Growth Factor Receptor-1 | 2 | 0.0 |
Mice | 9 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Cell Membrane/enzymology | 3 | 1.0 |
Endoplasmic Reticulum/enzymology | 2 | 8.0 |
Mitochondria/enzymology | 2 | 1.0 |
Fetal Growth Retardation/*ultrasonography | 4 | 100.0 |
Pre-Eclampsia/*ultrasonography | 2 | 100.0 |
*Ultrasonography, Prenatal | 6 | 19.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Culture Techniques | 2 | 0.0 |
Regression Analysis | 5 | 0.0 |
Embryonic and Fetal Development | 5 | 1.0 |
Ferritin/*blood | 2 | 3.0 |
Fetal Growth Retardation/*epidemiology | 4 | 100.0 |
Logistic Models | 8 | 1.0 |
Pregnancy/*blood | 3 | 1.0 |
Risk Factors | 22 | 0.0 |
Fetal Growth Retardation/metabolism | 2 | 40.0 |
*Apgar Score | 2 | 100.0 |
Chronic Disease | 2 | 0.0 |
*Birth Weight | 4 | 10.0 |
Fetal Growth Retardation/diagnosis | 2 | 28.0 |
Genetic Markers/genetics | 2 | 0.0 |
*Gestational Age | 4 | 6.0 |
*Mexican Americans | 2 | 15.0 |
Parity | 3 | 2.0 |
United States | 2 | 0.0 |
*Embryonic and Fetal Development | 4 | 3.0 |
*Apoptosis | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Signal Transduction | 5 | 0.0 |
Fetal Growth Retardation/ultrasonography | 2 | 66.0 |
*Pregnancy Outcome | 9 | 15.0 |
Ultrasonography, Doppler | 2 | 7.0 |
Ultrasonography, Prenatal/*methods | 2 | 28.0 |
Uterus/*blood supply | 3 | 12.0 |
Umbilical Veins | 2 | 0.0 |
Apgar Score | 3 | 13.0 |
*Pregnancy Complications | 3 | 7.0 |
Treatment Outcome | 2 | 0.0 |
Cell Division | 2 | 0.0 |
*Fetal Growth Retardation | 3 | 75.0 |
Enzyme Activation | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
Anthropometry | 2 | 0.0 |
Cohort Studies | 6 | 0.0 |
Confidence Intervals | 4 | 1.0 |
Odds Ratio | 3 | 0.0 |
Glucose/metabolism | 2 | 0.0 |
*Ultrasonography, Doppler | 2 | 33.0 |
Chromosome Mapping | 4 | 0.0 |
*Chromosomes, Human, Pair 1 | 5 | 1.0 |
Genetic Markers | 2 | 0.0 |
Infant | 2 | 0.0 |
Ploidies | 2 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Prognosis | 3 | 0.0 |
Karyotyping | 4 | 0.0 |
Embryonic and Fetal Development/*physiology | 3 | 6.0 |
Follow-Up Studies | 3 | 0.0 |
*Weight Gain | 3 | 17.0 |
Placental Insufficiency/*complications/pathology/physiopathology | 2 | 100.0 |
Incidence | 2 | 0.0 |
Maternal Age | 3 | 3.0 |
Heart Rate, Fetal | 2 | 66.0 |
Pulsatile Flow | 2 | 4.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 3 | 1.0 |
src-Family Kinases/*metabolism | 2 | 1.0 |
Placental Circulation | 2 | 40.0 |
Retrospective Studies | 8 | 0.0 |
Umbilical Arteries/*ultrasonography | 2 | 66.0 |
Insulin-Like Growth Factor Binding Protein 1/*blood | 2 | 11.0 |
Radioimmunoassay | 2 | 0.0 |
*Hypertension | 2 | 100.0 |
*Pregnancy Complications, Cardiovascular | 2 | 16.0 |
Fetal Growth Retardation/etiology | 5 | 41.0 |
Infant, Low Birth Weight | 2 | 7.0 |
Alabama/epidemiology | 2 | 28.0 |
*Infant, Small for Gestational Age | 2 | 11.0 |
Prevalence | 4 | 0.0 |
Poverty | 2 | 9.0 |
Amino Acid Sequence | 3 | 0.0 |
Binding Sites | 3 | 0.0 |
Molecular Sequence Data | 5 | 0.0 |
Pregnancy Outcome/*epidemiology | 2 | 50.0 |
Base Sequence | 5 | 0.0 |
Gene Expression | 2 | 0.0 |
Phosphotyrosine | 2 | 0.0 |
Multivariate Analysis | 3 | 0.0 |
Rheology | 2 | 2.0 |
Vascular Resistance | 2 | 3.0 |
Pregnancy Outcome | 3 | 1.0 |
Glomerular Filtration Rate | 2 | 1.0 |
Antibodies, Monoclonal | 2 | 0.0 |
In Vitro | 2 | 0.0 |
Cattle/*genetics | 2 | 1.0 |
*Chromosome Mapping | 3 | 0.0 |
DNA, Satellite/*genetics | 2 | 3.0 |
Linkage (Genetics) | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Fetal Growth Retardation/epidemiology/*ultrasonography | 2 | 100.0 |
Body Weight | 3 | 0.0 |
Smoking/adverse effects | 2 | 0.0 |
Socioeconomic Factors | 3 | 1.0 |
Weight Gain | 2 | 3.0 |
Fetus/anatomy & histology | 2 | 25.0 |
*Twins | 2 | 7.0 |
Body Mass Index | 2 | 0.0 |
Pregnancy/*physiology | 3 | 6.0 |
Aged, 80 and over | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
*Proto-Oncogenes | 4 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Alleles | 2 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
*Pregnancy, Multiple | 2 | 15.0 |
